Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 700-303-4 | CAS number: 84163-13-3
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
Acute toxicity: Oral
In an acute oral toxicity study in female Wistar rats, following the acute toxic class method in accordance with the OECD Guideline 423 and EU Method B.1 tris (Ott M; 2006), the LD50 of T001492 was established to be within the range of 300 - 2000 mg/kg bw. T001492 was found to be slightly toxic by the oral route and should be classified as Category 4 according to CLP regulation (EC) No 1272/2008.
In an acute oral toxicity study in rats, the LD50 of T001492 was found to be 77.10 (58.99 - 100.8) mg/kg (Janssen; 1988).
In a 5-day range-finding oral toxicity study in male and female Wistar rats, dose levels of 10, 30 or 100 mg/kg bw are proposed for the subsequent 28-day study with T001492 (RCC; 2006).
The studies were used in a weight-of-evidence approach.
Key value for chemical safety assessment
Acute toxicity: via oral route
Link to relevant study records
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- supporting study
- Study period:
- no data
- Reliability:
- 4 (not assignable)
- Rationale for reliability incl. deficiencies:
- documentation insufficient for assessment
- Reason / purpose for cross-reference:
- reference to same study
- Reason / purpose for cross-reference:
- reference to other study
- Principles of method if other than guideline:
- No data
- GLP compliance:
- not specified
- Test type:
- other: No data
- Species:
- rat
- Strain:
- not specified
- Sex:
- not specified
- Details on test animals or test system and environmental conditions:
- No data
- Route of administration:
- oral: unspecified
- Vehicle:
- not specified
- Details on oral exposure:
- No data
- Doses:
- 640 mg/kg bw
160 mg/kg bw
80 mg/kg bw
40 mg/kg bw - No. of animals per sex per dose:
- 5 rats per dose
- Control animals:
- not specified
- Details on study design:
- No data
- Statistics:
- No data
- Preliminary study:
- No data
- Dose descriptor:
- LD50
- Effect level:
- 77.1 mg/kg bw
- 95% CL:
- 58.99 - 100.8
- Mortality:
- 640 mg/kg bw: 5/5 mortality after 30 minutes
160 mg/kg bw: 5/5 mortality after 30 minutes
80 mg/kg bw: 3/5 mortality within 3 hours after administration
40 mg/kg bw: 0/5 mortality - Clinical signs:
- other: 80 mg/kg bw: convulsions or tremors. The 2 surviving rats behaved normal 24 hours afterwards.
- Body weight:
- other body weight observations
- Remarks:
- No data
- Gross pathology:
- No data
- Other findings:
- No data
- Interpretation of results:
- Category 3 based on GHS criteria
- Conclusions:
- The oral LD50-value of substance T001492 is 77.10 (58.99 - 100.8) mg/kg bw.
- Endpoint:
- acute toxicity: oral
- Remarks:
- 5-day range-finding oral toxicity study
- Type of information:
- experimental study
- Adequacy of study:
- supporting study
- Study period:
- 2006
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- study well documented, meets generally accepted scientific principles, acceptable for assessment
- Qualifier:
- no guideline followed
- Principles of method if other than guideline:
- dose range-finding toxicity study, daily administration by oral gavage
- GLP compliance:
- not specified
- Specific details on test material used for the study:
- SOURCE OF TEST MATERIAL
No information was provided in the report on the test item.
STABILITY AND STORAGE CONDITIONS OF TEST MATERIAL
No information was provided in the report on the test item.
FORM AS APPLIED IN THE TEST/
No information was provided in the report on the test item. - Species:
- rat
- Strain:
- Wistar
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: male and female rats, SPF-bred; no data available on source
- Acclimation: yes, no data available on acclimation period
No further information was provided in the report on the test animals.
ENVIRONMENTAL CONDITIONS
No information was provided in the report on the environmental conditions.
IN-LIFE DATES: No information was provided in the report on the in-life dates. - Route of administration:
- oral: gavage
- Vehicle:
- polyethylene glycol
- Remarks:
- PEG 300
- Details on oral exposure:
- VEHICLE
- Concentration in vehicle: not indicated
- Amount of vehicle: 5 mL/kg
MAXIMUM DOSE VOLUME APPLIED: 5 mL/kg - Doses:
- 0, 50, 150 and 500 mg/kg bw (daily administration for a period of 5 days)
- No. of animals per sex per dose:
- 4 animals per dose (two animals of each sex per group), 4 groups in total
- Control animals:
- yes
- Remarks:
- 4 animals, 2 males and 2 females
- Details on study design:
- - Duration of observation period following administration: animals were observed during acclimatization and treatment period only
- Frequency of observations and weighing: clinical signs, food consumption and body weights were recorded periodically. No further data available on frequency of observations.
- Necropsy of survivors performed: yes, at the end of the dosing period, the surviving animals were killed, necropsied and examined post mortem. - Statistics:
- No statistical analysis was performed.
- Key result
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- > 150 - < 500 mg/kg bw
- Based on:
- test mat.
- Mortality:
- Both females treated with 500 mg/kg bw of T1492 died on treatment day 2, the males treated with 500 mg/kg bw of T1492 died on day 3 and 4, respectively.
- Clinical signs:
- bodyweight loss
- convulsions
- irregular respiration
- other:
- Body weight:
- lower than 10% body weight loss
- Remarks:
- Both males treated with 500 mg/kg bw of T1492 showed obvious weight loss (-9%) between treatment days 1 and 3. Males and females treated with 150 mg/kg bw of T1492 showed lower body weight gains than controls between days 1 and 5, although this was more pronounced in males.
- Gross pathology:
- No test item related microscopical findings were present at any dose level. Both males treated with 500 mg/kg bw of T1492 showed foci in the thymus. One male treated with 500 mg/kg bw showed unilateral pelvic dilatation of the kidney.
- Other findings:
- Food consumption:
Food consumption during treatment was clearly reduced in all animals treated with 500 mg/kg bw and slightly reduced in males treated with 150 mg/kg bw of T1492.
Organ weight findings including organ / body weight ratios:
Absolute and relative thymus weights were reduced in males and females treated with 150 mg/kg bw of T1492 and absolute and relative spleen weights were reduced in males treated with 150 mg/kg bw of T1492. These changes are considered to be test-item related. - Interpretation of results:
- study cannot be used for classification
- Conclusions:
- Based on the results of this five-day dose range-finding study, dose levels of 10, 30 or 100 mg/kg bw/day are proposed for the subsequent 28-day study (RCC Study Number A46620) with T1492.
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 2006-04-04 (date of report to study director and test facility management)
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 423 (Acute Oral toxicity - Acute Toxic Class Method)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.1 tris (Acute Oral Toxicity - Acute Toxic Class Method)
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Test type:
- acute toxic class method
- Limit test:
- no
- Specific details on test material used for the study:
- SOURCE OF TEST MATERIAL
- Source and lot/batch No.of test material: IRA091
- Expiration date of the lot/batch: Unknown
- Purity: 100%
STABILITY AND STORAGE CONDITIONS OF TEST MATERIAL
- Storage condition of test material: At room temperature (20 ± 5 °C), light protected
- Stability under test conditions: Unknown in PEG 300 - Species:
- rat
- Strain:
- Wistar
- Sex:
- female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: female rats (nulliparous and non-pregnant), HanRCC:WIST (SPF-Quality); RCC Ltd., Laboratory Animal Services
- Age at study initiation: 12 weeks
- Weight at study initiation: 0.177 - 0.197 kg (range of three treatment groups)
- Fasting period before study: animals were deprived of food overnight prior to dosing and until 3-4 hours after administration of the test item. Water was available ad libitum.
- Housing: In groups of three in Makrolon type-4 cages with wire mesh tops and standard softwood bedding ('Lignocel' Schill AG, CH-4132 Muttenz/Switzerland).
- Diet (e.g. ad libitum): ad libitum, free access to pelleted rodent diet
- Water (e.g. ad libitum): ad libitum, free access to tap water.
- Acclimation period: at least 5 days before start of treatment under laboratory conditions.
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22 +/- 3°C
- Humidity (%): 30-70% (values above 70 % during cleaning process possible)
- Air changes (per hr): 10-15
- Photoperiod (hrs dark / hrs light): 12/12
IN-LIFE DATES: exact dates not reported - Route of administration:
- oral: gavage
- Vehicle:
- polyethylene glycol
- Remarks:
- PEG 300
- Details on oral exposure:
- VEHICLE
- Concentration in vehicle: The test item was diluted in vehicle (PEG 300) at a concentration of 0.03 g/mL and 0.2 g/mL
- Justification for choice of vehicle: The vehicle was chosen after a non-GLP solubility trial which was performed before the study initiation date. PEG 300 was found to be a suitable vehicle.
MAXIMUM DOSE VOLUME APPLIED: 10 ml/kg
DOSAGE PREPARATION (if unusual):
- Dose levels are in terms of the test item as supplied by the sponsor.
- The dose formulations were made shortly before each dosing occasion using a magnetic stirrer, a spatula and an Ultra-Turrax (Janke & Kunkel, D-79219 Staufen) as homogenizers.
The test item was weighed into a tared glass beaker on a suitable precision balance and the vehicle added (weight:volume). Homogeneity of the test item in the vehicle was maintained during administration using a magnetic stirrer.
CLASS METHOD (if applicable)
- Rationale for the selection of the starting dose: not indicated
TREATMENT
The animals received a single dose of the test item by oral gavage administration at 300 mg/kg body weight or 2000 mg/kg body weight after being fasted for approximately 17 to 18 hours (access to water was permitted). Food was provided again approximately 3 hours after dosing. - Doses:
- 2000 mg/kg, 300 mg/kg (single dosage each)
- No. of animals per sex per dose:
- 3 females per dose
- Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: 14 days (until day 15)
- Frequency of observations and weighing:
mortality/viability: Daily during the acclimatization period, approximately 30 minutes and at approximately 1, 2, 3 and 5 hours after administration on test day 1 (with the clinical signs) and twice daily during days 2-15.
body weights: days 1 (pre-administration), 8 and 15.
clinical signs: Daily during the acclimatization period, approximately 30 minutes and at approximately 1, 2, 3 and 5 hours after administration on test day 1. Once daily during days 2-15. All abnormalities were recorded.
- Necropsy of survivors performed: The two 2000 mg/kg treated animals and one 300 mg/kg treated animal which died spontaneously approximately 30 minutes or 3 hours after test item administration and the third animal of the 2000 mg/kg treated group which was killed in extremis approximately one hour after treatment were necropsied as soon as they were found dead or killed. The animal sacrificed for ethical reasons was killed by an intraperitoneal injection of Vetanarcol.
All surviving animals were killed at the end of the observation period by Carbon dioxide asphyxiation and discarded after macroscopic examinations were performed. No organs or tissues were retained. - Statistics:
- No statistical analysis was performed.
- Key result
- Sex:
- female
- Dose descriptor:
- LD50
- Effect level:
- > 300 - < 2 000 mg/kg bw
- Based on:
- test mat.
- Mortality:
- Two 2000 mg/kg treated animals were found dead approximately 30 minutes after treatment and the remaining animal treated at the same dose was killed in extremis for ethical reasons approximately 1 hour after treatment. Two out of six 300 mg/kg treated animals were found dead approximately 3 and 6 hour after treatment, respectively.
- Clinical signs:
- convulsions
- observations of tremors
- other:
- Body weight:
- other body weight observations
- Remarks:
- The body weight of the animals was within the range commonly recorded for this strain and age.
- Gross pathology:
- Liquid contents in the stomach, duodenum, jejunum, and ileum was noted in the two animals treated at 2000 mg/kg at the unscheduled necropsy. Lungs not collapsed were also noted in one of them. Liquid contents in the stomach and ileum and an empty jejunum was also noted in one 300 mg/kg treated animals at the unscheduled necropsy. Due to a technical error of the animal technician, no macroscopic findings were recorded for one 300 mg/kg treated animal.
- Interpretation of results:
- Category 4 based on GHS criteria
- Conclusions:
- The median lethal dose of T001492 after single oral administration to female rats, observed over a period of 14 days is: 300 mg/kg body weight < LD50 (female rat) < 2000 mg/kg body weight.
T001492 is to be classified as Category 4, harmful if swallowed (H302) following this study conclusion.
Referenceopen allclose all
Not applicable
Number of dead animals in each test group with 3 animals each:
Females 2000 mg/kg: two out of three
Females 300 mg/kg: two out of six (1 out of three in first group, 1 out of three in second group)
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- LD50
- Value:
- > 50 - < 300 mg/kg bw
Acute toxicity: via inhalation route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Acute toxicity: via dermal route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
Acute oral toxicity:
An acute oral toxicity study with T001492 according to the acute toxic class method 5 female Wistar rats was performed by Ott (2006). Single dosages of 300 mg/kg bw (2 groups of 3 animals) and 2000 mg/kg bw (1 group of 3 animals) were applied. The test material was formulated in propylene glycol (PEG 300) at concentrations of 0.03 g/mL and 0.2 g/mL respectively. The animals were observed for 14 days following administration. Mortality/viability was observed approximately 30 minutes and at approximately 1, 2, 3 and 5 hours after administration on test day 1 and twice daily during days 2-15. Body weight was observed at days 1, 8 and 15 and clinical signs were observed approximately 30 minutes and at approximately 1, 2, 3 and 5 hours after administration on test day 1 and once daily during days 2-15. Necrospy of survivors and macroscopic examination were also performed.
At 2000 mg/kg, two animals were found dead approximately 30 minutes after treatment and the remaining animal treated at the same dose was killed in extremis for ethical reasons approximately 1 hour after treatment. Two out of six 300 mg/kg treated animals were found dead approximately 3 and 6 hour after treatment, respectively.
At 2000 mg/kg, hunched posture, slight to moderate ruffled fur with slight to moderate sedation, slight to moderate tremor, half closed to closed eyes as well as ventral recumbency were noted. At 300 mg/kg, half closed to closed eyes, hunched posture, slightly to moderately ruffled fur and slight to moderate sedation, slight poor coordination, convulsions and tachypnea were noted. Furthermore, each animal was observed sitting individually in a corner of the cage one hour after treatment.
Liquid contents in the stomach, duodenum, jejunum, and ileum was noted in the two animals treated at 2000 mg/kg at the unscheduled necropsy. Lungs not collapsed were also noted in one of them. Liquid contents in the stomach and ileum and an empty jejunum was also noted in one 300 mg/kg treated animal at the unscheduled necropsy. Due to a technical error of the animal technician, no macroscopic findings were recorded for one 300 mg/kg treated animal.
The oral LD50 value of T001492 in Wistar rats was established to be within the range of 300-2000 mg/kg body weight, which classifies T001492 as slightly toxic by the oral route and should be classified as Category 4 according to the CLP regulation.
In addition, in an acute oral toxicty study performed by Janssen (1988), T001492 was orally administered at 40, 80, 160 and 460 mg/kg in rats (5 animals per dose). All animals died at 640 and 160 mg/kg and 3 out of 5 animals died at 80 mg/kg. The oral LD50-value of T001492 was considered to be 77.10 (58.99 - 100.8) mg/kg.
Also, a dose range-finding study was performed by Broich and Braun (2006). T001492 was daily administered at 50, 150 and 500 mg/kg bw as 5mL/kg in PEG300 by oral gavage in Wistar rats for a period of 5 days. The animals were observed during acclimatization and dosing period. Mortality, clinical signs, body weight and food consumption were observed and necropsy of survivors and macroscopic examination were also performed.
Both females treated with 500 mg/kg bw of T1492 died on treatment day 2, the males treated with 500 mg/kg bw of T1492 died on day 3 and 4, respectively.
Clinical signs included convulsions, half closed eyes, hunched posture, ruffled fur, body weight loss and labored breathing.
Necropsy of the decendents revealed no test item related macroscopical findings were present at any dose level. Absolute and relative thymus weights were reduced in males and females treated with 150 mg/kg bw of T1492 and absolute and relative spleen weights were reduced in males treated with 150 mg/kg bw of T1492. These changes are considered to be test-item related.
Dose levels of 10, 30 or 100 mg/kg bw/d are proposed for the subsequent 28-day study with T001492.
In a Janssen Expert Report performed by De Smedt, Van Gompel and Lammens (Expert Report JNJ-1782820-AAC, 2014-04-28) it was concluded that based on a (1) mortality percentage of 33% at 300 mg/kg in the study of 1998, (2) the high number of mortalities (2/2 F on day 2 and 2/2 M on day 3 and 4) in the 5-day range findings and (3) the internal communication (1988) with an LD50 value of 77.1 mg/kg, to consider an LD50 value between 50 and 300 mg/kg instead of the range of 300 -2000 mg/kg.
Studies referred to in the expert judgement:
Experiment Number | Study Type | Report conclusion |
RCC A28967 | Acute oral toxicity study in rats | 300 mg/kg < LD50 < 2000 mg/kg |
Internal communication | Acute oral toxicity study in rats | LD50 = 77.1 mg/kg |
RCC A71447 | 5 Day Range finding oral Toxicity study in rats | Selected dose levels for 28 days repeated dose tox study are 10, 30 and 100 mg/kg |
T001492 is to be classified as toxic if swallowed (Category 3) based on the Janssen expert statement.
Justification for classification or non-classification
Acute oral toxicity
Based on the results of the acute oral toxicity studies, the 5-day range finding study and the expert statement, an LD50 between 50 - 300 mg/kg bw is considered. According to the criteria laid down in Regulation (EC) No 1272/2008 on classification, labelling and packaging of substances and mixtures, T001492 should be classified as Category 3.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.